CROI 2023: METABOLIC AND OTHER COMPLICATIONS OF HIV INFECTION

Comorbid conditions have major impacts on the health, quality of life, and survival of people with HIV), particularly as they age. The 2023 Conference on Retroviruses and Opportunistic Infections (CROI 2023) featured excellent science related to specific comorbidities, such as cardiovascular disease (CVD), cancer, and obesity. Studies investigating factors that may contribute to CVD were featured prominently, such as mental health disorders, antiretroviral therapies, and activation of hormonal pathways. Other studies sought to understand the epidemiology of non-AIDS-defining cancers in people with HIV. As at previous CROI conferences, weight gain attributable to antiretroviral therapies was a major theme, and several abstracts focused on the important question of whether weight decreases after discontinuation of antiretroviral therapy (ART) regimens associated with weight gain. This review focuses on abstracts presented at CROI 2023 in these areas, highlighting those with the most clinical impact.